Fig. 2.

a–d Responses to treatment. NA not available, Anti-vit K anti-vitamin K, C1INH complement 1 esterase inhibitor, MTX methotrexate, TA tranexamic acid, P progestin. Numbers on the Y-axis represent the reference number for each study; n indicates the number of patients included from each study. Not shown in (c): Mansi et al., 13 of 24 patients had partial response to tranexamic acid. Not shown in (d): Zazzali et al., in 208 patients treated with omalizumab, the mean proportion of AE-free days was 90.1–95.8 % vs. 88.7 % for placebo